196 related articles for article (PubMed ID: 27378345)
1. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
[TBL] [Abstract][Full Text] [Related]
2. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
3. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Aamdal E; Inderberg EM; Ellingsen EB; Rasch W; Brunsvig PF; Aamdal S; Heintz KM; Vodák D; Nakken S; Hovig E; Nyakas M; Guren TK; Gaudernack G
Front Immunol; 2021; 12():663865. PubMed ID: 34046035
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
5. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW; Lorentzen CL; Martinenaite E; Ellebaek E; Donia M; Holmstroem RB; Klausen TW; Madsen CO; Ahmed SM; Weis-Banke SE; Holmström MO; Hendel HW; Ehrnrooth E; Zocca MB; Pedersen AW; Andersen MH; Svane IM
Nat Med; 2021 Dec; 27(12):2212-2223. PubMed ID: 34887574
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA
J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345
[TBL] [Abstract][Full Text] [Related]
8. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
Front Immunol; 2018; 9():2145. PubMed ID: 30283461
[No Abstract] [Full Text] [Related]
9. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.
Sarnaik AA; Yu B; Yu D; Morelli D; Hall M; Bogle D; Yan L; Targan S; Solomon J; Nichol G; Yellin M; Weber JS
Clin Cancer Res; 2011 Feb; 17(4):896-906. PubMed ID: 21106722
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM
Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
12. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Zahm CD; Johnson LE; McNeel DG
Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
[TBL] [Abstract][Full Text] [Related]
13. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for malignant melanoma.
Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.
Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C
Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
[TBL] [Abstract][Full Text] [Related]
17. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
Dalle S; Mortier L; Corrie P; Lotem M; Board R; Arance AM; Meiss F; Terheyden P; Gutzmer R; Buysse B; Oh K; Brokaw J; Le TK; Mathias SD; Scotto J; Lord-Bessen J; Moshyk A; Kotapati S; Middleton MR
BMC Cancer; 2021 May; 21(1):642. PubMed ID: 34051732
[TBL] [Abstract][Full Text] [Related]
18. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
Schreiber S; Kämpgen E; Wagner E; Pirkhammer D; Trcka J; Korschan H; Lindemann A; Dorffner R; Kittler H; Kasteliz F; Küpcü Z; Sinski A; Zatloukal K; Buschle M; Schmidt W; Birnstiel M; Kempe RE; Voigt T; Weber HA; Pehamberger H; Mertelsmann R; Bröcker EB; Wolff K; Stingl G
Hum Gene Ther; 1999 Apr; 10(6):983-93. PubMed ID: 10223732
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
